Regadenoson Injection, Solution
NDC Package 68083-175-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Regadenoson injection is   is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. This formulation utilizes a injection, solution delivery system. Marketed by Gland Pharma Limited, this product is identified by NDC 68083-175 and is authorized under FDA application ANDA207320.

Identification & Billing

NDC Package Code
68083-175-10
Package Description
10 VIAL in 1 CARTON / 5 mL in 1 VIAL (68083-175-01)
Product Code
68083-175
11-Digit Billing Format
68083017510

Clinical Specifications

Proprietary Name
Regadenoson
Non-Proprietary Name
Regadenoson
Substance Name
Regadenoson
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
REGADENOSON .08 mg/mL
Pharmacologic Class
Usage Information
Regadenoson injection  is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.

Regulatory & Marketing

Labeler Name
Gland Pharma Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA207320
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-12-2022
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68083-175-10 identifies a specific commercial package of 10 vial in 1 carton / 5 ml in 1 vial (68083-175-01) of Regadenoson, a human prescription drug labeled by Gland Pharma Limited. This injection, solution is formulated for intravenous use and contains regadenoson as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gland Pharma Limited on July 12, 2022. The current certification is valid through December 31, 2026.

How is this Gland Pharma Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68083017510. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68083-175-10
11-Digit CMS (5-4-2)
68083-0175-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.